Why did VAXX stock fall so sharply on 19 Jan 2026?

The sharp fall was driven by very low liquidity and small executed volume of 257 shares. No major company announcement matched the timing. Wide bid-ask spreads on microcap stocks can amplify percent moves.

What is Meyka AI's rating for VAXX stock?

Meyka AI rates VAXX with a score out of 100: Score 57.56, Grade C+, Suggestion HOLD. The grade factors benchmark, sector, financials, metrics, and forecasts and is informational only.

What price targets and forecast exist for VAXX stock?

Meyka AI's forecast model projects a quarterly figure of $0.09. Given the current $0.0001 price, this implies a large model-based upside. Conservative near-term target: $0.01; optimistic: $0.09.

How should traders manage risk with VAXX stock?

Use small position sizes, limit orders, and strict stops. Monitor NASDAQ quotes and company filings. Expect wide spreads and large slippage in microcap trading.

Where can I find official VAXX stock quotes and news?

For live market data and company context, see Nasdaq's VAXX page and aggregated coverage on Markets Insider: [Nasdaq VAXX](https://www.nasdaq.com/market-activity/stocks/vaxx) and [Markets Insider search results](https://markets.businessinsider.com/searchresults?_search=%E8%A5%BF%E5%AE%89%E9%84%A0%E9

US Stocks

VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook

ByHuzaifa Zahoor January 20, 2026

At market close on 19 Jan 2026, VAXX stock (Vaxxinity, Inc., NASDAQ) plunged 99.00% to $0.0001. The move came on extremely low liquidity with volume 257 shares versus a 50-day average volume of 17,301.00. We view this as a liquidity-driven collapse rather than a fresh clinical update. This piece explains the price action, financial context, technicals, and our model forecast for VAXX stock.